Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Harbin Pharmaceutical Group Co's quarterly Other Current Payables
increased
from Sep. 2025 (¥1,881 Mil) to Dec. 2025 (¥1,919 Mil) but then
declined
from Dec. 2025 (¥1,919 Mil) to Mar. 2026 (¥1,902 Mil).
Harbin Pharmaceutical Group Co's annual Other Current Payables
declined
from Dec. 2023 (¥1,978 Mil) to Dec. 2024 (¥1,841 Mil) but then
increased
from Dec. 2024 (¥1,841 Mil) to Dec. 2025 (¥1,919 Mil).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Harbin Pharmaceutical Group Co Other Current Payables Chart
Harbin Pharmaceutical Group Co Other Current Payables Calculation
Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.
What does a Other Current Payables of ¥1,902 Mil mean?
Harbin Pharmaceutical Group Co (SHSE:600664) has a Other Current Payables of ¥1,902 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Harbin Pharmaceutical Group Co and its competitors.
Is Harbin Pharmaceutical Group Co's Other Current Payables too high?
Harbin Pharmaceutical Group Co's current Other Current Payables is ¥1,902 Mil. Overall, Harbin Pharmaceutical Group Co has a GF Score™ of 68/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Harbin Pharmaceutical Group Co's Other Current Payables compare to ZTS?
Harbin Pharmaceutical Group Co's Other Current Payables of ¥1,902 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Drug Manufacturers company?
A good Other Current Payables depends on the Drug Manufacturers industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Harbin Pharmaceutical Group Co and its competitors. Harbin Pharmaceutical Group Co's current Other Current Payables is ¥1,902 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harbin Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Harbin Pharmaceutical Group Co (SHSE:600664) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥3.51, compared to a current price of ¥5.67 — trading 61.5% above its estimated fair value. The current Other Current Payables is ¥1,902 Mil. Harbin Pharmaceutical Group Co's overall GF Score™ is 68/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Harbin Pharmaceutical Group Co (SHSE:600664), the current Other Current Payables is ¥1,902 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Harbin Pharmaceutical Group Co (SHSE:600664) Overvalued in 2026?
Based on GuruFocus' analysis, Harbin Pharmaceutical Group Co stock appears to be overvalued.
The current stock price of ¥5.67 is trading 61.5% above its estimated GF Value™ of ¥3.51.
GuruFocus considers Harbin Pharmaceutical Group Co to be Significantly Overvalued.
Key valuation signals for SHSE:600664:
Other Current Payables: ¥1,902 Mil
GF Value™: ¥3.51 vs. price of ¥5.67 (61.5% above fair value)
No single metric tells the full story. See the SHSE:600664 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Harbin Pharmaceutical Group Co Ltd is engaged in manufacturing, trading and research and development of pharmaceuticals. The company is organized into seven business segments - Antibiotics, Small-Molecular drug preparations, OTC and healthcare products, Modern Chinese medicines, Biopharmaceuticals, Animal vaccines, and medicine circulations. The company sells its products across China and fifty other countries. Some of its brands are - Hayao, Sanjing, Gaizhonggai, Hutong, and Shiyitang.
68GF Score
Get the complete analysis for SHSE:600664
Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600664 has been successfully added to your 
